- Home
- SAVA vs GF Comparison
SAVA vs GF Comparison
Compare SAVA & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- GF
- Stock Information
- Founded
- SAVA 1998
- GF 1990
- Country
- SAVA United States
- GF Germany
- Employees
- SAVA N/A
- GF N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- GF Investment Managers
- Sector
- SAVA Health Care
- GF Finance
- Exchange
- SAVA Nasdaq
- GF Nasdaq
- Market Cap
- SAVA 70.5M
- GF 155.4M
- IPO Year
- SAVA N/A
- GF N/A
- Fundamental
- Price
- SAVA $1.76
- GF $11.00
- Analyst Decision
- SAVA Buy
- GF
- Analyst Count
- SAVA 3
- GF 0
- Target Price
- SAVA $54.50
- GF N/A
- AVG Volume (30 Days)
- SAVA 807.5K
- GF 28.1K
- Earning Date
- SAVA 05-08-2025
- GF 01-01-0001
- Dividend Yield
- SAVA N/A
- GF 0.82%
- EPS Growth
- SAVA N/A
- GF N/A
- EPS
- SAVA N/A
- GF N/A
- Revenue
- SAVA N/A
- GF N/A
- Revenue This Year
- SAVA N/A
- GF N/A
- Revenue Next Year
- SAVA N/A
- GF N/A
- P/E Ratio
- SAVA N/A
- GF N/A
- Revenue Growth
- SAVA N/A
- GF N/A
- 52 Week Low
- SAVA $1.15
- GF $7.38
- 52 Week High
- SAVA $42.20
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- SAVA 54.92
- GF 73.34
- Support Level
- SAVA $1.45
- GF $10.30
- Resistance Level
- SAVA $1.67
- GF $11.00
- Average True Range (ATR)
- SAVA 0.11
- GF 0.12
- MACD
- SAVA 0.05
- GF 0.06
- Stochastic Oscillator
- SAVA 87.50
- GF 98.98
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.